Turner K C, Brouwer K L
Division of Pharmaceutics, School of Pharmacy, The University of North Carolina at Chapel Hill, 27599-7360, USA.
Drug Metab Dispos. 1997 Sep;25(9):1017-21.
The effect of probenecid (PRB) on factors regulating the hepatic disposition of acetaminophen glucuronide (AG) was investigated in vitro. Potential interactions in metabolism or binding to cytosolic proteins were examined. In the absence of PRB, AG formation in rat hepatic S9 fractions was saturable (V(max) = 2.77 +/- 0.36 nmol/ min/mg protein; K(M) = 18.0 +/- 0.92 mM). PRB significantly decreased V(max), but not K(M), for AG formation, consistent with noncompetitive inhibition. Various models were fit to the AG formation rate vs. acetaminophen (APAP) and PRB concentration data to elucidate the mechanism of inhibition by PRB. A partial noncompetitive inhibition model (K(i) = 1.10 +/- 0.01 mM) described the data best based on model selection criteria. AG did not bind to the cytosolic protein ligandin (glutathione S-transferase A1). These data indicate that PRB is a potent partial noncompetitive inhibitor of acetaminophen glucuronidation in vitro. PRB-associated alterations in AG hepatic disposition in vivo are not due to altered binding of AG to GSTA1 but may be attributed in part to impaired AG formation.
在体外研究了丙磺舒(PRB)对调节对乙酰氨基酚葡萄糖醛酸苷(AG)肝脏处置的因素的影响。研究了代谢或与胞质蛋白结合方面的潜在相互作用。在不存在PRB的情况下,大鼠肝脏S9组分中AG的形成是可饱和的(V(max)=2.77±0.36 nmol/分钟/毫克蛋白;K(M)=18.0±0.92 mM)。PRB显著降低了AG形成的V(max),但不影响K(M),这与非竞争性抑制一致。将各种模型拟合到AG形成速率与对乙酰氨基酚(APAP)和PRB浓度的数据,以阐明PRB的抑制机制。根据模型选择标准,部分非竞争性抑制模型(K(i)=1.10±0.01 mM)对数据的拟合最佳。AG不与胞质蛋白配体蛋白(谷胱甘肽S-转移酶A1)结合。这些数据表明,PRB在体外是对乙酰氨基酚葡萄糖醛酸化的强效部分非竞争性抑制剂。PRB在体内引起的AG肝脏处置改变并非由于AG与GSTA1结合的改变,而可能部分归因于AG形成受损。